Featured

Latest — Articles

Latest — Articles

Latest — Articles

Qualcomm 2025 M&A Recap: Big Strides in AI, IoT, and Auto
Author Image

Yessica Jain

Feb 3, 2026

In a single year, Qualcomm completed six acquisitions across AI and semiconductor infrastructure. The message is clear: as its traditional modem business faces long-term erosion, Qualcomm is racing to transform itself from a communications specialist into a fully integrated AI platform company.

Qualcomm 2025 M&A Recap: Big Strides in AI, IoT, and Auto

Feb 3, 2026

Qualcomm 2025 M&A Recap: Big Strides in AI, IoT, and Auto
Author Image

Yessica Jain

Feb 3, 2026

In a single year, Qualcomm completed six acquisitions across AI and semiconductor infrastructure. The message is clear: as its traditional modem business faces long-term erosion, Qualcomm is racing to transform itself from a communications specialist into a fully integrated AI platform company.

The EA Buyout: A $55 Billion Bet on the Future of Gaming, or a Debt-Fueled Mistake?
Author Image

Shaurya Vohra

Feb 2, 2026

Leveraged buyouts thrive on predictability. Video games do not. EA’s $55 billion take-private deal forces one of the most creatively volatile industries to operate under one of the most financially rigid ownership structures.

The EA Buyout: A $55 Billion Bet on the Future of Gaming, or a Debt-Fueled Mistake?

Feb 2, 2026

The EA Buyout: A $55 Billion Bet on the Future of Gaming, or a Debt-Fueled Mistake?
Author Image

Shaurya Vohra

Feb 2, 2026

Leveraged buyouts thrive on predictability. Video games do not. EA’s $55 billion take-private deal forces one of the most creatively volatile industries to operate under one of the most financially rigid ownership structures.

J&J’s Big Swing: The Single Pill Acquisition That Shook Biopharma
Author Image

Cayden Liu

Nov 19, 2025

Johnson & Johnson dropped $14.6 billion on a company whose value rests almost entirely on one psychiatric drug. Caplyta may be a blockbuster, or it may be the most expensive overreach in biotech since 2022. This is a high-risk, high-premium gamble at a moment when Big Pharma can’t afford missteps.

J&J’s Big Swing: The Single Pill Acquisition That Shook Biopharma

Nov 19, 2025

J&J’s Big Swing: The Single Pill Acquisition That Shook Biopharma
Author Image

Cayden Liu

Nov 19, 2025

Johnson & Johnson dropped $14.6 billion on a company whose value rests almost entirely on one psychiatric drug. Caplyta may be a blockbuster, or it may be the most expensive overreach in biotech since 2022. This is a high-risk, high-premium gamble at a moment when Big Pharma can’t afford missteps.

The New Corporate Guillotine: How One Email Can End a CEO
Author Image

Shaurya Vohra

Nov 15, 2025

One activist email can now do what used to take a full proxy war: topple a CEO. With record campaigns and the Universal Proxy Card turning every board seat into open combat, corporate governance has become faster, louder, and far more ruthless than ever before.

The New Corporate Guillotine: How One Email Can End a CEO

Nov 15, 2025

The New Corporate Guillotine: How One Email Can End a CEO
Author Image

Shaurya Vohra

Nov 15, 2025

One activist email can now do what used to take a full proxy war: topple a CEO. With record campaigns and the Universal Proxy Card turning every board seat into open combat, corporate governance has become faster, louder, and far more ruthless than ever before.

The $5.3 Billion Roller Coaster: How Jana Partners and Travis Kelce Plan to Save Six Flags
Author Image

Samuel Regelman

Nov 8, 2025

When a company with $5.3 billion in debt and a 47% stock collapse attracts a hedge fund and an NFL star, it’s not charity, it’s strategy. Jana Partners and Travis Kelce are betting they can turn Six Flags from a sinking relic into a comeback story worth watching.

The $5.3 Billion Roller Coaster: How Jana Partners and Travis Kelce Plan to Save Six Flags

Nov 8, 2025

The $5.3 Billion Roller Coaster: How Jana Partners and Travis Kelce Plan to Save Six Flags
Author Image

Samuel Regelman

Nov 8, 2025

When a company with $5.3 billion in debt and a 47% stock collapse attracts a hedge fund and an NFL star, it’s not charity, it’s strategy. Jana Partners and Travis Kelce are betting they can turn Six Flags from a sinking relic into a comeback story worth watching.

The $2.1 Billion Sleep Deal: Alkermes’s Biggest Gamble Yet
Author Image

Yessica Jain

Nov 6, 2025

Alkermes just placed a $2.1 billion bet on sleep with a sleep drug few investors saw coming. Alkermes isn’t just buying Avadel, it’s buying time and maybe the future of mental health medicine.

The $2.1 Billion Sleep Deal: Alkermes’s Biggest Gamble Yet

Nov 6, 2025

The $2.1 Billion Sleep Deal: Alkermes’s Biggest Gamble Yet
Author Image

Yessica Jain

Nov 6, 2025

Alkermes just placed a $2.1 billion bet on sleep with a sleep drug few investors saw coming. Alkermes isn’t just buying Avadel, it’s buying time and maybe the future of mental health medicine.

Load More

Load More

Load More